Abstract A099: Preliminary pharmacodynamic characterization in patients with platinum-resistant ovarian cancer treated with nemvaleukin in combination with pembrolizumab
Bibliographic record
Abstract
Abstract Introduction: Platinum-resistant ovarian cancer (PROC) is associated with poor treatment outcomes, leaving an unmet need for effective therapy. Nemvaleukin alfa selectively binds to the intermediate-affinity IL-2 receptor, activating and expanding immune effector cells with minimal expansion of T regulatory cells (Tregs). The ARTISTRY-1 trial has shown clinical activity of nemvaleukin in combination with pembrolizumab in PROC, which is being further tested in the Phase 3 ARTISTRY-7 trial. Here, we characterize pharmacodynamic (PD) effects in blood in PROC patients treated with nemvaleukin in combination with pembrolizumab. Methods: Whole blood samples were collected from patients with ovarian cancer at baseline and during treatment in the ARTISTRY-1 study (NCT02799095) and were analyzed by flow cytometry to examine immune cell modulation. Patients received nemvaleukin 3μg/kg Q5D daily + pembrolizumab 200 mg in 21-day (D) cycles and were assessed at baseline (Pre-Rx C1D1) and longitudinally (C1D8 and C2D8). Immunophenotyping of whole blood (absolute counts, cells/μL) was conducted for T cells, B cells, natural killer (NK) cells, Tregs, and subtypes. Best overall response is as of 27 Mar 2023 with scans occurring every 6 (±1) weeks. Results: Patients included N=14 at baseline and N=11 for longitudinal assessments. Higher baseline numbers of CD4 central memory cells predicted longer PFS for the nemvaleukin+pembrolizumab combination (CD4 low: mPFS=9.4 wks vs CD4 high: mPFS=54.8 wks). Higher baseline numbers of B cells and memory T cells (CD8 central and CD4 effector) also showed a trend towards longer PFS. Longitudinal analysis showed that during treatment there was a 6-fold expansion of NK cells and a 2.7-fold expansion of CD8 cells, with minimal change in the number of Tregs. NK cell ratio with cutoff of 1.1 at C2D8/C1D8 correlated with response and trended towards longer PFS.Conclusion: These preliminary PD data suggest immune activation after treatment in PROC, therefore warranting further study of nemvaleukin combined with anti-PD-1/PD-L1 agents in PROC. Further validation of the promising PD data at the tumor site using paired biopsies is being conducted in the ongoing ARTISTRY-3 trial in PROC patients treated with nemvaleukin. Citation Format: Ira Winer, Ulka N. Vaishampayan, Lucy Gilbert, Shipra Gandhi, Vamsidhar Velcheti, Rita Dalal, Yangchun Du, Sarah Donatelli, Sonali Panchabhai, James F. Strauss, Sarina Piha-Paul. Preliminary pharmacodynamic characterization in patients with platinum-resistant ovarian cancer treated with nemvaleukin in combination with pembrolizumab [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr A099.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".